TIDMSBTX

RNS Number : 1300F

SkinBioTherapeutics PLC

16 February 2018

SkinBioTherapeutics plc

Notice of interim results

Manchester, UK - 16 February 2018 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, will publish its interim results for the six months to 31 December 2017 on 21 February 2018.

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company.

-Ends-

For more information, please contact:

 
 SkinBioTherapeutics plc          Tel: +44 (0) 161 468 
  Dr. Cath O'Neill, CEO                           2760 
  Doug Quinn, CFO 
 Cairn Financial Advisers         Tel: +44 (0) 20 7213 
  LLP (Nominated Advisor)                         0880 
  Tony Rawlinson / Emma Earl 
  / Richard Nash 
 Turner Pope Investments          Tel: +44 (0) 20 3621 
  (Joint Broker)                                  4120 
  Ben Turner / James Pope 
 
  Northland Capital (Joint        Tel: +44 (0) 20 3861 
  Broker)                                         6625 
  John Howes / Tom Price 
 Instinctif Partners              Tel: +44 (0) 20 7457 
  Melanie Toyne-Sewell /                          2020 
  Deborah Bell                  SkinBio@instinctif.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R), is based upon discoveries made by CEO Dr. Cath O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix(R) platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix(R) platform has beneficial attributes applicable to each of these areas.

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix(R). The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix PLC (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising GBP4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORLLFIIFLIRLIT

(END) Dow Jones Newswires

February 16, 2018 05:02 ET (10:02 GMT)

Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Skinbiotherapeutics Charts.
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Skinbiotherapeutics Charts.